Ditching the lawnmower may have unexpected health benefits, according to experts
While these campaigns were launched to support pollinators and biodiversity, some experts claim that skipping the mower could actually be good for your health.
Mowing, raking, digging and lifting might seem like harmless weekend chores, but according to Dr. Michael Policastro, a board-certified emergency physician and medical toxicologist in Cincinnati, Ohio, they can be physically taxing.
"Lawn and garden work is physically demanding and can lead to muscle strains, back pain and joint injuries," Policastro told Fox News Digital.
The repetitive motions, awkward postures and sometimes heavy loads involved in yard work can strain the body in ways that accumulate over time, the doctor cautioned.
Even the act of pushing a lawnmower may not be as harmless as it looks.
"Vibrations from lawnmowers can strain your lower back, and poor posture while pushing or steering equipment can lead to pain in your back, knees and wrists," Policastro noted.
Failing to warm up or stretch before tackling the lawn only raises the risk of fatigue or injury, which can result in chronic pain over time.
Chemical pesticides and herbicides involved in lawn care can carry their own set of risks, especially when airborne, Policastro cautioned.
"Pesticide sprays can also drift in the air, making it easy to breathe in harmful chemicals without realizing it," he said.
There could be a psychological upside to ditching the mower and embracing a natural yard.
Several mental health professionals agreed that lively, unmanicured spaces can foster mindfulness and well-being.
"Being in a green, natural environment can promote mindfulness and a sense of calm," Greg Adelstein, a licensed mental health counselor and owner of Ellie Mental Health Clinic in Hollywood, Florida, told Fox News Digital.
"It also provides a sense of accomplishment and purpose, which can boost self-esteem."
Letting nature reclaim the yard could also mean fewer chemicals and health hazards, some experts say.
Fox News Digital previously reported on a study that linked exposure to nature with a reduction in people's experience of pain. This suggests the potential health benefits of a more natural lawn that promotes everyday access to wild plants and animals.
"Gardening promotes mindfulness and can lower cortisol levels, helping you feel calmer."
Natural lawns and gardens can also help combat loneliness by encouraging community engagement through shared gardening or conservation efforts, according to Elena Saldamando, a licensed clinical social worker and director of Ellie Mental Health Clinic in Avalon Park, Florida.
Despite the potential risks, tending to a lawn can present some benefits when done safely, experts say.
"Gardening promotes mindfulness and can lower cortisol levels, helping you feel calmer," Saldamando told Fox News Digital.
"Watching how the light hits a leaf, listening to birds chirp, feeling soil and dirt in your hands, smelling the flowers and seeing vegetables grow can be very grounding."
To reduce the physical strain of mowing and other yard work, Policastro recommended taking regular breaks, using ergonomic tools and maintaining proper posture.
For more Health articles, visit www.foxnews.com/health
It's also important to work in a well-ventilated area and to wear a mask or respirator when handling dusty materials or applying chemicals, according to the doctor.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (''2510') anticipated before the end of 2025 Updated '2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025 World Conference on Lung Cancer (WCLC) by ImmuneOnco DALLAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ('Instil') (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2025 financial results and provided a corporate update. Recent Highlights: In June, announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer In July, announced the Investigational New Drug (IND) application for '2510 was cleared by the U.S. FDA In July, ImmuneOnco, Instil's collaborator, announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of '2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco In August, ImmuneOnco announced that an abstract has been accepted for poster presentation at IASLC's 2025 World Conference on Lung Cancer (September 6th-9th, 2025), which will provide updated results from additional patients with relapsed/refractory squamous-NSCLC treated with '2510 as monotherapy Second Quarter 2025 Financial and Operating Results: As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 million, which consisted of $7.7 million in cash and cash equivalents, approximately $0.2 million in restricted cash, $84.1 million in marketable securities, and $11.7 million in long-term investments, compared to $115.1 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2024, consisting of $8.8 million in cash and cash equivalents, $1.8 million in restricted cash, and $104.5 million in marketable securities. Instil expects that its cash, cash equivalents, marketable securities and long-term investments as of June 30, 2025 will enable it to fund its operating plan beyond 2026. In-process research and development expenses were $10.0 million for both the three and six months ended June 30, 2025, compared to nil for both the three and six months ended June 30, 2024. Research and development expenses were $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively, compared to $2.9 million and $10.2 million for the three and six months ended June 30, 2024, respectively. General and administrative expenses were $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively, compared to $10.7 million and $23.1 million for the three and six months ended June 30, 2024, respectively. Restructuring and impairment charges were $0.5 million and $16.6 million for the three and six months ended June 30, 2025, respectively, compared to $0.5 million and $4.8 million for three and six months ended June 30, 2024, respectively. Net loss per share, basic and diluted were $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively, compared to $2.29 and $6.03 for the three and six months ended June 30, 2024, respectively. Non-GAAP net loss per share, basic and diluted, were $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively, compared to $1.57 and $3.95 for the three and six months ended June 30, 2024, respectively. Note Regarding Use of Non-GAAP Financial Measures In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles ('GAAP'). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil's operating results. In addition, these non-GAAP financial measures are among the indicators Instil's management uses for planning purposes and to measure Instil's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. About Instil Bio Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'exploring,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'projects,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential of AXN-2510/IMM2510, clinical development of AXN-2510/IMM2510, including the initiation of clinical trials for AXN-2510/IMM2510 and the generation and presentation of clinical data for AXN-2510/IMM2510 and the timing thereof; research, development, regulatory and clinical plans for AXN-2510/IMM2510; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for manufacturing and generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, particularly collaborator-led clinical trials, as well as the risks that results obtained in any clinical trials to date may not be indicative of results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process and the sufficiency of Instil's cash resources; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts: Investor Relations:1-972-499-3350 investorrelations@ INSTIL BIO, FINANCIAL DATA (Unaudited; in thousands, except share and per share amounts) Selected Condensed Consolidated Balance Sheet Data June 30, 2025 December 31, 2024 Cash, cash equivalents, restricted cash, marketablesecurities and long-term investments $ 103,632 $ 115,145 Total assets $ 230,986 $ 263,567 Total liabilities $ 99,316 $ 94,131 Total stockholders' equity $ 131,670 $ 169,436 Condensed Consolidated Statements of Operations Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: In-process research and development $ 10,000 $ — $ 10,000 $ — Research and development 6,743 2,921 12,114 10,177 General and administrative 6,157 10,706 15,266 23,130 Restructuring and impairment charges 540 508 16,622 4,783 Total operating expenses 23,440 14,135 54,002 38,090 Loss from operations (23,440 ) (14,135 ) (54,002 ) (38,090 ) Interest income 1,044 1,919 2,219 3,981 Interest expense (1,582 ) (1,999 ) (2,680 ) (3,980 ) Other rental income 2,242 — 4,484 — Other income (expense), net 342 (702 ) 385 (1,130 ) Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Weighted-average shares used incomputing net loss per share, basic anddiluted 6,596,975 6,503,913 6,564,994 6,503,913 INSTIL BIO, of GAAP to Non-GAAP Net Loss and Net Loss per Share (Unaudited; in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net loss $ (21,394 ) $ (14,917 ) $ (49,594 ) $ (39,219 ) Adjustments: Non-cash stock-based compensationexpense 1,824 4,173 5,319 8,688 Restructuring and impairmentcharges 540 508 16,622 4,783 Non-GAAP net loss $ (19,030 ) $ (10,236 ) $ (27,653 ) $ (25,748 ) Net loss per share, basic and diluted $ (3.24 ) $ (2.29 ) $ (7.55 ) $ (6.03 ) Adjustments: Non-cash stock-based compensationexpense per share 0.28 0.64 0.81 1.34 Restructuring and impairmentcharges per share 0.08 0.08 2.53 0.74 Non-GAAP net loss per share, basicand diluted* $ (2.88 ) $ (1.57 ) $ (4.21 ) $ (3.95 ) Weighted-average shares outstanding,basic and diluted 6,596,975 6,503,913 6,564,994 6,503,913 * Non-GAAP net loss per share, basic and diluted may not total due to in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
How good are the school lunches in Rhode Island? Pretty good, report says. See ranking
School in Rhode Island will be starting soon, which means another year of school lunches. As a parent, you're not exactly there with your children to assess the cafeteria food's quality, but you would hope the school lunches are at least healthy and nutritious for the kids there. It would be nice to know for sure, though. In Rhode Island, a recent report found the odds of your child having a healthy lunch are pretty good. ProCare Therapy released the State of School Lunch Report, ranking which states in the U.S. have the healthiest school lunches and which states are lacking in that department, and ranked Rhode Island No. 8 in the U.S. The report took into account participation in the Farm to School program, which includes activities for school gardens and farms so that children can learn about where their food comes from, and other programs. How healthy are Rhode Island school meals With a score of 62.38, Rhode Island was ranked No. 8 out of the 50 states and Washington, D.C., included in the report's list. With this ranking, the Ocean State is one of the most dedicated places in the country toward providing healthy school meals to children, the report said. Vermont took the top spot. "Hawaii also leads in the percentage of schools serving local foods, with Virginia, Washington D.C., Rhode Island, and Oregon following suit, where over 87% of schools provide locally grown food to their students," the report said. The top 10 places in the U.S. for healthiest school meals in the report are: Vermont Hawaii Washington, D.C. West Virginia Delaware Virginia Oregon Rhode Island New York Alaska More: Are the feds coming for coffee milk in schools? They might not even find it on the menu. Here's what you need to know about free lunches in Rhode Island. Are school lunches free in Rhode Island You can apply for free or reduced-price school lunches for your children in Rhode Island, according to the state government website. "The cost of breakfast and lunch varies by school, but regardless of the cost, your children may qualify for free meals or for reduced-price meals," the website said. Rin Velasco is a trending reporter. She can be reached at rvelasco@ This article originally appeared on The Providence Journal: RI ranks No. 8 in healthy school lunches in the U.S., report says Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
LIO Launches Next-Generation Inpatient Mental Health Platform with Advanced Rounding, Monitoring, and Compliance Tools
The platform's capabilities will support frontline staff and facility leaders, and promote patient safety WILMINGTON, Del., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIO today announced the launch of its new all-in-one platform for inpatient mental health services, featuring a compliance reporting suite, next generation digital observations, and adaptive monitoring modes. LIO, formerly Oxehealth, has expanded its footprint in the U.S. 500% since the start of 2025. LIO's enhanced platform and recent U.S. expansion will help solve some of the most critical issues impacting America's mental healthcare system. 'This platform launch marks a pivotal moment for inpatient mental health care,' said Todd Haedrich, CEO of LIO. 'LIO represents a fundamental evolution of our capabilities, addressing the most pressing challenges facing providers today and for the next decade while helping facilities enhance patient care and improve operational efficiency.' LIO uses a unique, patented infrared system to remotely monitor patients, providing contactless measurement of sleep and vital signs through FDA-cleared software, along with additional insights into patient activity, all without disturbing patients. LIO allows clinicians to conduct observations and maintain patient safety wherever they are on the unit, including shared spaces and corridors. The platform also provides operational oversight capabilities for hospital leaders, ensuring care is delivered safely and consistently while meeting regulatory standards. LIO builds on more than 15 years of close collaboration with providers across the globe and the large-scale deployment of its technology across hundreds of mental health facilities. Grounded in a robust, peer-reviewed evidence base, the platform has demonstrated measurable improvements in safety, quality, and efficiency — with results showing that a 100-bed facility using LIO can prevent more than 400 safety incidents each year, save 27,500 hours of staff time, and achieve approximately $700,000 in annual savings. 'As clinical providers, our job is to keep our patients safe and make sure they are receiving the best care possible,' said Mike Genovese, MD, Chief Medical Officer at Access TeleCare and LIO Board Member. 'LIO brings together everything we need in one platform — digital rounding, ambient monitoring and compliance reporting. It enables us to go beyond checking regulatory boxes; frontline staff and clinical leaders now have the insights to focus on what really matters: delivering exceptional patient care.' Implementation of the new technology is quick and minimally disruptive, with a typical unit installation taking just 1-2 weeks. LIO's roadmap includes the rollout of patient recognition capabilities for identity confirmation and enterprise-level analytics tools to help provider networks measure safety performance across sites, detect operational bottlenecks, and improve staff efficiency at scale. 'This is just the beginning,' added Haedrich. 'We are building for the future of mental health — and we're inviting providers, partners, and innovators to join us.' About LIOLIO is the all-in-one platform for inpatient mental health. It brings together digital rounding, ambient monitoring and compliance reporting in a single, purpose-built solution – helping facilities run safe and high-performing services. With a fully contactless design that promotes patient comfort, and FDA-cleared software that meets the highest standards for clinical accuracy, LIO supports both frontline teams and hospital leaders to make informed, data-driven decisions. As a result, the platform reduces risk, enhances efficiency and strengthens adherence to regulatory standards – improving the experience of care for everyone involved. Trusted by hundreds of facilities in the US and UK, and backed by dozens of peer-reviewed studies, LIO fits seamlessly into the way hospitals work today while paving the way for tomorrow's advancements. For more information, visit Press Contact:Dori YoungLIO@ in to access your portfolio
